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Diabetes increases the risk of pulmonary hypertension and is associated with alterations in pulmonary vascular function. Still, it is 
not clear whether alterations in the phenotype of pulmonary endothelium induced by diabetes are distinct, as compared to 
peripheral endothelium. In the present work, we characterized differences between diabetic complications in the lung and aorta 
in db/db mice with advanced diabetes. Male, 20-week-old db/db mice displayed increased HbA1c and glucose concentration 
compatible with advanced diabetes. Diabetic lungs had signs of mild fibrosis, and pulmonary endothelium displayed 
significantly ultrastructural changes. In the isolated, perfused lung from db/db mice, filtration coefficient (Kf,c) and contractile 
response to TXA2 analogue were enhanced, while endothelial NO-dependent modulation of pulmonary response to hypoxic 
ventilation and cumulative production of NO− 2 were impaired, with no changes in immunostaining for eNOS expression. In 
turn, 6-keto-PGF1α release from the isolated lung from db/db mice was increased, as well as immunostaining of 
thrombomodulin (CD141). In contrast to the lung, NO-dependent, acetylcholine-induced vasodilation, ionophore-stimulated 
NO− 2 generation, and production of 6-keto-PGF1α were all impaired in aortic rings from db/db mice. Although eNOS 
immunostaining was not changed, that of CD141 was clearly lowered. Interestingly, diabetes-induced nitration of proteins in 
aorta was higher than that in the lungs. In summary, diabetes induced marked ultrastructural changes in pulmonary 
endothelium that were associated with the increased permeability of pulmonary microcirculation, impaired NO-dependent 
vascular function, with compensatory increase in PGI2 production, and increased CD141 expression. In contrast, endothelial 
dysfunction in the aorta was featured by impaired NO-, PGI2-dependent function and diminished CD141 expression. 
1. Introduction 
Diabetes induces profound alterations in systemic circulation 
and is the leading cause of macro- and microangiopathies 
such as diabetic retinopathy, nephropathy, and myocardial 
infarct, as well as peripheral artery disease [1–3]. The detri-
mental effects of diabetes in the lungs are less clinically 
apparent. However, epidemiological and experimental data 
suggested that insulin resistance and diabetes affect the lung. 
In diabetic subjects, the risk of pulmonary hypertension 
and pulmonary embolism was increased [4]. Interestingly, 
several studies have suggested that diabetes results in the 
impairment of respiratory function [5–7] and increased 
susceptibility to allergic response/inflammation induced with 
LPS or airway bacterial infection [8–10]. Structural changes 
in blood-alveolar barrier and diffusion impairment in vivo 
have also been reported [11, 12]. Despite these reports, the 
possible detrimental effects of insulin resistance and diabetes 
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on the pulmonary circulation have received little attention, 
and therefore research on this aspect of the pathophysiology 
of diabetes has largely been neglected. To the best of our 
knowledge, there are only few reports directly comparing 
systemic and pulmonary circulation response to diabetes in 
the same experimental model. Such an approach could give 
a better understanding of similarities and differences between 
diabetes-induced changes in pulmonary and peripheral 
circulation [13, 14]. 
Furthermore, although peripheral endothelial dysfunc-
tion represents a well-recognized hallmark of peripheral dia-
betic macro- and microangiopathies [2, 7, 15], the evidence 
on the development of pulmonary endothelial dysfunction 
in diabetes is rather conflicting. Both the presence and lack 
of impairment of NO-dependent pulmonary endothelial 
function have been reported [13, 16, 17]. In turn, an increase 
in pulmonary microvascular permeability without changes in 
eNOS or with increased iNOS expression has also been dem-
onstrated [13, 16–18]. 
Similarly, reports on diabetes-induced changes in PGI2 
production in the pulmonary circulation are also not 
consistent. In streptozotocin-treated rats, basal PGI2 produc-
tion and stimulated PGI2 production in pulmonary 
circulation were reported to increase or to remain unchanged 
[14, 19, 20]. Interestingly, PGI2 is a major regulator of the 
expression of thrombomodulin (CD141) [21, 22], which 
complexes with thrombin (IIa) and activates protein C to 
act as an anticoagulant and endothelial protective mediator 
[23]. Thus, the changes in the activity of PGI2 may result in 
the alteration in the activity of thrombomodulin, despite 
the fact that previous studies reported no changes [24–26]. 
Given the nonconsistent literature, the aim of the present 
work was to characterize changes in pulmonary endothelial 
function in comparison with changes in peripheral endothe-
lial function in the aorta, with special focus on NO- and 
PGI2-dependent pathways. For this purpose, male db/db mice 
at the age of 20 weeks with features of advanced diabetes were 
used, and pulmonary and peripheral endothelial functions 
and NO and PGI2 activities were analyzed in the isolated, 
perfused diabetic lung, or in the aortic rings, respectively. 
2. Material and Methods 
2.1. Animals. 20-week-old db/db (BKS.Cg-Dock7m 
+/+LeprdbJ) and C57BL/6J mice, purchased from Charles 
River Laboratories, were housed in specific pathogen-free 
conditions (SPF) and fed with a standard laboratory diet 
and water ad libitum. 
All experimental procedures used in the present study 
were conducted according to the Guidelines for Animal Care 
and Treatment of the European Communities and the Guide 
for the Care and Use of Laboratory Animals published by the 
US National Institutes of Health (NIH Publication number 
85-23, revised 1996). All procedures were approved by the 
local Jagiellonian University Ethical Committee on Animal 
Experiments (number 53/2009). 
2.2. Blood Count, HbA1c, and Basal Biochemistry in 
Plasma. Blood was collected from anaesthetized animals 
(pentobarbital, 140 mg/kg, i.p.) via the right ventricle to 
a syringe with nadroparine (end concentration: 10 U/ml) 
for analysis of blood count and HbA1c, and the rest of the 
sample were centrifuged to obtain plasma (1000g, 5min, 
4 ° C). Complete blood count was analyzed within 15 minutes 
after collection (by automatic blood counter ABC Vet, 
HORIBA). HbA1c and total hemoglobin concentrations were 
measured using a biochemical analyser (ABX Pentra 400, 
HORIBA), and the ratio was given as a percentage of HbA1c. 
Glucose, aspartate aminotransferase, alanine aminotrans-
ferase, creatinine, albumin, and total protein were measured 
using colorimetric methods (ABX Pentra 400, HORIBA). 
2.3. Histological Analysis of the Lungs. The lungs were 
removed under anaesthesia and fixed in 4% buffered forma-
lin (24 h) and were then dehydrated, embedded in paraffin, 
cut into 5 μm sections on Accu-Cut® SRM™ 200 Rotary 
Microtome, and stained with either hematoxylin and eosin 
(H&E), Masson Trichrome, Orcein and Methyl Scarlet Blue 
(OMSB [27]), or Picro Sirius Red. Light microscopic exami-
nation and photographic documentation were performed 
using an Olympus BX53F microscope equipped with a digital 
camera. 
2.4. Assessment of Changes in Lung Ultrastructure. The chest 
of anaesthetized rats was opened, and samples of lung tissue 
were cut and fixed immediately using a mixture of 2.5% 
glutaraldehyde and 2% freshly prepared paraformaldehyde 
in 0.1 mol/L cacodylate buffer at pH 7.4. The lung tissue 
was fixed for 12 h at 4 ° C. Then, the lungs were postfixed in 
buffered 2% osmium tetroxide, dehydrated in a graded 
ethanol series and propylene oxide, and embedded in Epon 
812. The ultrathin sections were stained according to routine 
protocol with uranyl acetate and lead citrate and were exam-
ined and documented by transmission electron microscopy 
(Jem 1011, JEOL, Japan). 
2.5. Immunohistochemistry of Lung Tissue. After excision, 
lung tissues were fixed with 4% formalin solution (10 min) 
and placed in 50% OCT for cryopreservation (24 h), then 
snap frozen at −80 ° C. Blocks were cut into 10 μm-thick 
cross-sectional slides. 5% normal goat serum (Jackson 
Immuno) or 2.5% horse serum (Vector Labs) and 2% filtered 
dry milk were applied to minimalize nonspecific binding of 
antibodies. For indirect immunohistochemical detection of 
von Willebrand factor (vWF), thrombomodulin (CD141), 
endothelial nitric oxide synthase (eNOS), vascular cell 
adhesion molecule 1 (VCAM-1), and macrophage content 
(MAC3), sections were incubated with rabbit anti-vWF 
polyclonal Ig (Abcam), rat polyclonal anti-CD141 Ig (BD 
Bioscience), mouse monoclonal anti-eNOS Ig (BD Biosci-
ence), rat anti-VCAM-1 monoclonal Ig (Millipore), or rat 
anti-MAC3 monoclonal Ig (Thermo), respectively (1 h). 
Antibodies were applied at concentrations of 5μg/ml or 
10μg/ml (dilution 1 : 100–1 : 300 of stock solution). After 
rinsing in PBS, secondary biotinylated horse anti-rabbit 
(Vector Labs), goat anti-mouse, goat anti-rat, or goat anti-
rabbit (Jackson Immuno) antibodies were applied for 
30min. At a third step of staining, Cy3-conjugated 
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streptavidin (Jackson Immuno) and Hoechst 33258 solution 
were used. 
2.6. Assessment of Endothelial Function in the Isolated Lung 
Preparation. Trachea in anesthetized mice were cannulated, 
and the lungs were ventilated with positive pressures at 
a rate of 90 breaths/min (VCM module from Hugo Sachs 
Electronic (HSE)). After laparotomy, the diaphragm was 
cut and nadroparine at a dose of 600 I.U. was injected into 
the right ventricle to prevent microthrombi formation during 
the surgical procedure. Then, the animals were exsangui-
nated by incision of the left renal artery. The lungs were 
exposed via a median sternotomy. The pulmonary artery 
and left atrium were cannulated via the right and left 
atrium, respectively. 
Immediately after cannulation, the lung/heart block was 
dissected from the thorax. Using tracheal cannula, the iso-
lated lung was mounted in a water-jacketed (38 ° C), air-tight 
glass chamber (HSE) and ventilated with negative pressures. 
The lungs were perfused with low-glucose DMEM with 4% 
albumin and 0.3% HEPES; the pH of perfusate was 
maintained at 7.35 throughout the whole experiment by 
continuous addition of 5% CO2 to the inspiratory air, using 
a peristaltic pump (ISM 834, HSE) at a constant flow (CF) 
of about 1.50 ml/min. The venous pressure was set between 
2 and 5 cmH2O. The end-expiratory pressure in the chamber 
was set to be −3 cmH2O, and inspiratory pressure was 
adjusted between −6 and −10 cmH2O to yield the initial tidal 
volume (TV) of about 0.2 ml. Breathing frequency was set to 
be 90 breaths/min, and a duration of inspiration versus 
expiration was 1 : 1 in each breath. Every 5min throughout 
the experiments, a deep breath of end-inspiratory pressure 
of −21 cmH2O was automatically initiated by VCM module 
(HSE) to avoid atelectasis. Airflow velocity was measured 
with a pneumotachometer tube connected to a differential 
pressure transducer (HSE), from which the value of respira-
tory tidal volume was determined. In experiments with 
constant pressure perfusion (CP), CP mode was turned on 
just after placing the lungs in the artificial thorax. The PAP 
was set to be around 3 cmH2O. The venous pressure was set 
between 2 and 5 cmH2O. 
Both arterial and venous pulmonary pressures (PAP, 
PVP) were continuously monitored by ISOTEC pressure 
transducers (HSE) connected to a perfusion line on arte-
rial and venous sides, respectively. The weight of the lungs 
was monitored by a weight transducer (HSE). TC, PAP, 
PVP, and lung weight data were acquired by the PC trans-
ducer card and subsequently analyzed by Pulmodynpulmo 
software (HSE). 
All lung preparations were allowed to equilibrate for the 
first 15 min of perfusion with fresh buffer until baseline 
PAP, PVP, TV, and weight were stable. At this time point, 
weight of the lung (the value of which varied considerably 
between experiments) was set to zero. 
2.6.1. Hypoxic Pulmonary Vasoconstriction (HPV). HPV was 
evoked by 10-minute intervals of hypoxic ventilation with a 
mixture of 95% N2 and 5% CO2. HPV, measured as changes 
in PAP, was stabilized after 5 minutes. After cessation of 
acute hypoxia, PAP returned to a basal level. There was 
a 10-minute interval of normal ventilation between HPV 
procedures. HPV was repeated twice, then L-NAME 
(300 μM) was added to the perfusate and recirculated 
through the lung for 10 minutes, and HPV response was 
repeated twice again. Although TV, PAP, PVP, and weight 
were continuously monitored throughout the experiment, 
for data analysis, only maximum increase in PAP (ΔPAP) 
elicited by HPV was taken. TV, PVP, and weight did not 
change significantly during HPV. 
2.6.2. Vasoreactivity. After equilibration, U46619 (1μM) 
was added to the perfusate, which resulted in an increase 
of PAP, but other parameters of isolated lungs did not 
change. For data analysis, only maximum increase of 
PAP (ΔPAP) was taken. 
2.6.3. Pulmonary Microcirculation Permeability. In equili-
brated isolated lung, perfused with constant pressure, the 
pulmonary venous pressure was increased to obtain PVP 
1.5 cmH2O above PAP and was maintained at this level 
through 15 minutes. This resulted in an increase in weight 
of the lungs; other parameters were stable. After 15 minutes, 
PVP was set to basal value, and the process was repeated. The 
filtration coefficient (Kf,c) was calculated based on recordings 
for 5 minutes after PVP increase [28]. 
2.6.4. Biochemical Measurements. 6-keto-PGF1α and NO− 2 / 
NO− 3 concentrations were measured in samples of effluents 
collected after 15 minutes of equilibration of isolated lungs 
perfused with constant flow, and then 5 and 45 minutes 
after recirculation of the perfusate was started. To assess 
the enzymatic source of 6-keto-PGF1α, a sample was taken 
before and after administration of COX-2 selective inhibitor 
(DuP-697, 1 μM) or nonselective COX-1/COX-2 inhibitor 
(indomethacin, 1 μM). 
2.7. Assessment of Endothelial Function in the Isolated Aortic 
Rings. The thoracic aorta was quickly dissected out of the 
chest of anaesthetized mice, and the surrounding fat/connec-
tive tissue was removed in Krebs-Henseleit (KH) solution 
(mM: NaCl 118.0, CaCl2 2.52, MgSO4 1.16, NaHCO3 24.88, 
K2PO4 1.18, KCl 4.7, glucose 10.0, pyruvic acid 2.0, and 
EDTA 0.5). Then, the aorta was cut into 2-3 mm rings, which 
were mounted between two pins filled with 5ml of KH 
solution chambers (37 ° C, pH7.4, gassed with carbogen: 
95% O2, 5% CO2) of wire myograph (620M, Danish Myo 
Technology, Denmark). The unstretched aortic rings were 
allowed to equilibrate for 30 minutes. Then, the resting 
tension of the rings was increased stepwise to reach 10mN, 
and the rings were washed with fresh KH solution and 
incubated to equilibrate for the next 30 mins. 
After equilibration, the viability of the tissue was exam-
ined by contractile responses to potassium chloride (KCl 
30mM, 60mM), and then the aortic rings were contracted 
with phenylephrine (Phe 0.01–3.0 μM) to obtain maximal 
possible constriction of the rings. All tissue responses were 
recorded, using a data acquisition system and recording soft-
ware (PowerLab, LabChart, and ADInstruments, Australia). 
The aortic rings were next contracted with phenylephrine 
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to obtain 80–90% of maximal contraction, and the 
endothelial-dependent response was assessed using cumula-
tive concentrations of acetylcholine (ACh 0.01–10 μM). After 
washout, the vessels were again contracted with phenyleph-
rine, and endothelial-independent vasodilation to cumulative 
concentrations of sodium nitroprusside (SNP 0.001–1μM) 
was assessed. The relaxation response was expressed as a per-
centage of the precontraction induced by phenylephrine. 
2.8. Assessment of Prostacyclin (PGI2) Production in the 
Isolated Aortic Rings. The concentration of PGI2, produced 
by aortic rings, was quantified on the basis of the formation 
of 6-keto-PGF1α, a stable metabolite of PGI2. The aorta rings 
were preincubated for 15 minutes on the thermoblock 
(Liebisch Labortechnik) at a temperature of 37 ° C, in 250μl 
KH buffer, gassed with carbogen in the absence or in the 
presence of COX-2 selective inhibitor (DuP-697, 1 μM) or 
nonselective COX-1/COX-2 inhibitor (indomethacin, 5 μM). 
All inhibitors were dissolved in DMSO, and then control 
rings were incubated with addition of the same amount of 
DMSO (1μl/ml). 
Aortic rings were then incubated for 60 minutes, and 
samples of effluents were collected after 3 and 60 minutes. 
After the experiment, aortic rings were dried (1 h, 50 ° C) 
and weighed. 6-keto-PGF1α concentration in the effluents 
was measured using an EIA kit (Enzo, Life Technologies). 
Results were expressed as the change in 6-keto-PGF1α con-
centration between 60 and 3 minutes of ring incubation 
and normalized to dry weight of aortic rings (pg/ml/mg). 
2.9. Assessment of Nitrite Production in the Isolated Aortic 
Rings. Basal NO production by the aorta was estimated by 
measurements of nitrite, a primary stable product of nitric 
oxide oxidation, and thus considered relevant for estimation 
of NO synthesis by the aortic endothelium. Segments from 
the aortic arch were longitudinally opened, placed in 96-
well plates facing up with endothelium, and incubated for 
one hour in 120 μl KH buffer at 37 ° C, using a specially 
designed closed chamber (BIO-V(Noxygen)) that was 
equilibrated with carbogen gas mixture (95% O2, 5% CO2). 
The nitrite concentration after back reduction to NO was 
measured using the gas-phase chemiluminescent reaction 
between NO and ozone using a Sievers∗ Nitric Oxide Ana-
lyzer NOA 280i. The reduction of nitrites was performed in 
a closed glass chamber containing a reducing agent (1% wt/ 
vol of KI in acetic acid) to convert nitrite to NO. The inde-
pendent calibration on fresh NaNO2 standard solution was 
prepared for every experiment before measurements of series 
of samples after each refilling of glass reaction chamber, 
according to the manufacturer’s instructions (Sievers∗ Nitric 
Oxide Analyzer NOA 280i). The limit of detection was 
around 10 nM of nitrite. Multiple blank samples (without 
aortic rings) were used to monitor nitrite contamination 
in the buffer and/or by laboratory atmosphere in every 
set of experiments. The averaged blank signal from a 
blank sample in a given experiment was subtracted as a 
background signal. Samples were kept on ice and measured 
directly after experiments. Nitrite concentration was 
expressed as ng/ml/mg of dry weight of aortic rings. 
2.10. Immunohistochemistry in Aorta. Dissected thoracic 
aorta, cleared of the surrounding fat/connective tissue in 
Krebs-Henseleit (KH) solution, was fixed with 4% formalin 
solution (10 min), embedded in 50% OCT for cryopreserva-
tion (24 h), snap frozen at −80 ° C, and cut in 10μm-thick 
cross-sectional slides for immunohistochemistry. 2.5% horse 
serum (Vector Labs) and 2% dry milk were applied to mini-
malize nonspecific binding of antibodies. For von Willebrand 
factor (vWF) staining, rabbit anti-mouse vWF polyclonal Ig 
(Abcam) was used, followed by biotinylated horse anti-
rabbit Ig (Vector Labs) and Cy3-streptavidin (Jackson 
Immuno), as described above. Nuclei were counterstained 
with Hoechst 33258 (Sigma-Aldrich). Images were acquired 
using an Axio Observer D2 fluorescent microscope, and 
fluorescence parameters were analyzed automatically by 
Columbus software (PerkinElmer). 
2.11. Dot Blot Analysis in Aorta and Lungs. Protein expres-
sion and modification were assessed by standard dot blot 
analysis using established protocols [29]. 3-Nitrotyrosine-
(3NT-) positive proteins were assessed by dot blot analysis 
of protein homogenates in aorta and lungs, which were 
transferred to a Protran BA85 (0.45 μm) nitrocellulose 
membrane (Schleicher & Schuell, Dassel, Germany) by 
a Minifold I vacuum dot-blot system (Schleicher & Schuell, 
Dassel, Germany) [30]. A mouse monoclonal 3NT antibody 
(1 : 1000, Upstate Biotechnology, MA, USA) was used for 
dot blot analysis. Detection and quantification of all blots 
were performed by ECL with peroxidase anti-mouse 
(1 : 10,000, Vector Lab., Burlingame, CA). Densitometric 
quantification of antibody-specific bands was performed 
with a ChemiLux Imager (CsX-1400 M, Intas, Göttingen, 
Germany) and Gel-Pro Analyzer software (Media Cyber-
netics, Bethesda, MD). 
3. Statistical Analysis 
Results are presented as the mean ± SEM. The normality of 
the results was analysed using the D’Agostino & Pearson 
omnibus normality test and the Shapiro-Wilk test. To 
calculate statistical significance, a paired Student’s t-test, 
Mann-Whitney test, or unpaired Student t-test was used. 
Post hoc analysis was calculated using Dunn’s multiple 
comparisons test. 
4. Results 
4.1. Basal Characteristics of db/db Mice. 20-week-old db/ 
db mice were obese (body weight: 53.77 ± 0.18 versus 
29.5 ± 0.12 g, db/db and control, resp.; P < 0  05) and had 
increased HbA1c (15.38 ± 1.7 versus 4.12 ± 1.36%, db/db 
and control, resp.; P < 0  05) and fasting glucose concentra-
tion in plasma (40.64 ± 5.41 versus 8.66 ± 1.24 mmol/l, db/ 
db and control, resp.; P < 0  05) as compared to control mice. 
In addition to hyperglycaemic profile, db/db mice displayed 
signs of liver injury (increased plasma AST, ALT, e.g., for 
ALT: 141.90 ± 19.68 versus 38.02 ± 2.80, db/db and control, 
resp.; P < 0  001) and kidney injury (increased plasma 
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Figure 1: Histology of the lungs and ultrastructure of pulmonary endothelial cells from the control (a, c, e, g) and diabetic (b, d, f, h) lungs 
(db/db mice). (a) Histological structure of the control lungs. (b) Inflammation in the lung tissue: increased amount of cells (including 
granulocytes and macrophages) and (d) collagen in parenchyma of the diabetic lung tissue as compared to control; visible decreased aerial 
space in diabetic lungs as compared to the control (c). (e) Microphotographs of ultrastructure of the control lungs—blood-air barrier 
(alveolar–capillary barrier) with normal endothelial layer. (f, g, h) Microphotographs of ultrastructure of the lungs from the db/db mice. 
(f) Capillary endothelial cells (arrows) with numerous plasmalemmal vesicles (caveolae) on thickened blood-air barrier (bab). In the 
center: collapsed pulmonary alveoulus, on the right: blood platelet (plt) inside the vessel. (g) A presence of convoluted apical region in 
endothelial cells with cytoplasmic extensions on hyperplastic basal laminae enriched with elastine (el); on the bottom: red blood cell (rbc). 
(h) Endothelial cells of various heights (arrows) separated by thickened blood-air barrier (bab) from pulmonary alveolus; neighbouring 
red blood cell (rbc). Representative images of at least 3 independent experiments. 
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Figure 2: Comparison of basal parameters of the isolated, perfused lungs amongst diabetic and control animals. (a) No change in basal 
pulmonary pressure, although (b) enhanced reactivity to thromboxane analogue in the lungs of the diabetic mice (U-44619, 1 μM, control 
n = 5, diabetes n = 5). (c) Decreased compliance without changes in (d) resistance of the lungs (control n = 5, diabetes n = 6). (e) Increased 
filtration coefficient in the diabetic pulmonary circulation (control n = 5, diabetes n = 5). Data are presented as the means± SEM. ∗P < 0 05. 
creatinine 62.90 ± 63.61 versus 46.74 ± 7.02 μmol/(L∗ cm2), 
db/db and control, resp.; P < 0 05). 
4.2. Histology and Ultrastructure of Lungs in db/db Mice. 
Lungs from db/db mice displayed inflammation, as evidenced 
by multicellular (including granulocytes, macrophages) infil-
trations in the interstitial space (HE staining, Figure 1(b)) as 
compared to the control group (Figure 1(a)); mild fibrosis 
(increased amount of collagen), as evidenced by Trichrome 
staining (Figure 1(d)) as compared to the control group 
(Figure 1(c)); and endothelial inflammation, as evidenced 
by increased VCAM-1 expression in pulmonary endothelium 
(480,937 ± 70,112 versus 247,193 ± 64,821 AU, db/db and 
control, resp.; P = 0 07). Interestingly, ultrastructural investi-
gations confirmed the presence of numerous macrophages 
(often lying next to each other) in the lungs from db/db mice, 
as compared to control mice, and they were also detected as 
adhering to endothelium (data not shown). Moreover, semi-
thin sections of lung tissue revealed diminished area of alveoli 
(34.13 ± 4.25 versus 50.75 ± 3.83, db/db and control, resp.). 
Capillary endothelial cells displayed protruded apical regions 
into the capillary lumen, increased area of sarcoplasmic retic-
ulum, plasmalemmal vesicles (caveolae), and sometimes 
presence of multivesicular bodies or lysosomes. 
One of the typical features of db/db pulmonary microcir-
culation was the hyperplasia of basal lamina in db/db 
(Figures 1(f) and 1(h)) that was not evident in control sam-
ples (Figures 1(e) and 1(g)). Thickness of capillaries’ basal 
lamina ranges from 0.1 μm to 0.35 μm, compared to 
0.05 μm in controls. Additionally, septa separating lung alve-
oli in db/db were thicker, with abundant collagen fibrils and 
probably contained also elastin fibrils marked by an uncon-
trasted area in the thin sections routinely stained with uranyl 
acetate and lead citrate (Figures 1(f) and 1(h)), which was 
also not seen in control samples (Figures 1(e) and 1(g)). 
4.3. Alterations in Pulmonary Vascular Function and 
Inflammation in the Isolated, Perfused Lung from db/db Mice 
4.3.1. Changes in Basal Pulmonary Parameters and 
Vasoreactivity. The basal pulmonary artery pressures in the 
isolated, perfused lungs (bPAP) were comparable in db/db 
and control mice (PAP: 4.70 ± 0.62 versus 5.20 ± 0.30 
cmH2O, db/db and control, resp., Figure 2(a)). Vasoreactivity 
to thromboxane A2 analogue U46619 was increased 
threefold in the isolated lungs from db/db mice (ΔPAP: 
4.83 ± 0.32 versus 1.43 ± 0.69 cmH2O, db/db and control, 
resp.; P = 0 073) (Figure 2(b)). Compliance but not resistance 
was decreased in db/db mice (compliance: 0.016 ± 0.002 
versus 0.030 ± 0.003 ml/cmH2O, db/db and control, resp.; 
P < 0 05; resistance: 1.09 ± 0.04 versus 0.99 ± 0.04 cmH2O/ 
ml/s, db/db and control, resp.; Figures 2(c) and 2(d)). 
4.3.2. Changes in Permeability Coefficient (Kf,c). In the 
isolated, perfused lung, an increase in pulmonary venous 
pressure resulted in slow, reversible weight gain of the lungs, 
both in control and db/db mice. Calculation of Kf,c revealed a 
higher filtration coefficient in the diabetic lungs as compared 
with the control lungs (8.70 ± 1.33 versus 5.02 ± 0.27 ml/ 
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min/cmH2O/100 g of body weight, db/db and control, 
resp.; P < 0  05, Figure 2(e)). 
4.3.3. Impairment of NO-Dependent Regulation of Hypoxic 
Pulmonary Vasoconstriction (HPV). In the isolated, per-
fused lung from control mice, episodes of hypoxic ventila-
tion resulted in an increase of pulmonary arterial pressure 
(PAP) without significant changes in other parameters 
of isolated lung preparation (Figure 3(a)). In control 
lungs, the nonselective inhibitor of nitric oxide synthases, 
L-NAME, augmented HPV response (ΔPAP: 0.87 ± 0.32 
versus 2.73 ± 0.44 cmH2O, before and after L-NAME, resp.; 
P < 0  05). However, in the isolated, perfused lung from 
db/db mice, the effect of L-NAME on HPV was substan-
tially lost (ΔPAP: 0.60 ± 0.04 versus 1.17 ± 0.12 cmH2O, 
before and after L-NAME, resp.; P < 0  05) suggesting 
impaired NO-dependent function. L-NAME did not modify 
basal PAP (Δ basal PAP after L-NAME: 0.17 ± 0.03 versus 
0.19 ± 0.06 cmH2O, in control and db/db mice, resp.). 
4.3.4. Nitrite/Nitrate (NO− 2 /NO3−) and Prostacyclin (PGI2) 
Production. In effluents from the isolated, perfused lungs, 
basal NO2−/NO− 3 concentrations were comparable in both 
groups (e.g., NO− 2 0.40 ± 0.04 versus 0.56 ± 0.19 μM, db/db 
and control, resp., Figures 3(b) and 3(c)). The cumulative 
concentrations of NO− 2 from the diabetic lungs (see Methods 
for details) were significantly lower (ΔNO− 2 : -0.04± 0.04 
versus 0.11 ± 0.05 μM, db/db and control, resp.), but there 
were no changes in NO3 − concentrations (Figures 3(d) 
and 3(e)). The cumulative concentration of stable PGI2 
metabolite, 6-keto-PGF1α, in the effluents from the iso-
lated diabetic lungs was higher than that in the control 
(Δ6-keto-PGF1α: 223.5± 57.91 versus 95.06 ± 24.00 pg/ml, 
db/db and control, resp.) and was blunted after COX-2 
inhibitor, DuP-697 (Figure 3(f)). 
4.3.5. Markers of Vascular Inflammation. In diabetic lungs, 
immunohistochemical staining intensity of vascular adhe-
sion molecule-1 (VCAM-1) was increased by a trend as com-
pared to the control samples (Figure 4(a)). Von Willebrand 
factor (vWF) and thrombomodulin (CD141) (but not eNOS) 
were higher in the diabetic lungs than in the control lungs 
(Figures 4(b)–4(d)). All together these results support an 
increased inflammatory state in the pulmonary system of 
diabetic mice. 
4.4. Impairment of Endothelial Function and Inflammatory 
Markers in the Aorta of db/db Mice. Vasoreactivity to phen-
ylephrine (30 μM) in the aortic rings from db/db mice was 
increased (not shown). Acetylcholine- (ACh-) induced 
endothelium-dependent vasodilation was decreased for all 
concentrations in db/db mice, while sodium nitroprusside-
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Figure 4: Immunohistochemical profile of the diabetic lungs. (a) Inflammation in vascular wall related to increased immunostaining of 
vascular cell adhesion molecule 1 (VCAM-1) and (b) von Willebrand factor in the lungs of the diabetic mice (both for VCAM-1 and 
vWF: control n = 4, diabetes n = 4). (c) No change in eNOS immunostaining in the diabetic lungs as compared to the control 
(control n = 4, diabetes n = 4). (d) Increased thrombomodulin (CD141) immunostaining in the diabetic lungs as compared to the control 
(control n = 4, diabetes n = 4). Data are presented as the means± SEM. ∗∗P < 0 01, ∗∗∗ P < 0 001. 
(SNP-) induced response was preserved as compared to the 
control group (Figures 5(a) and 5(b)). Impairment of func-
tional response was supported by a decline in ionophore-
stimulated NO− 2 production in the aortic rings from the db/ 
db mice (33.88± 10.01 versus 173.30 ± 77.79 nM, db/db and 
control, resp.; P < 0 05). Basal NO− 2 concentrations in buffer 
from the incubated aortic rings were comparable in both 
groups (27.17 ± 13.43 versus 32.75 ± 11.68 nM, db/db and 
control, resp.), whereas the effect of the NOS inhibitor, 
L-NIO, was striking in the aorta of the control mice 
and absent in the diabetic group (Figure 5(c)). COX-2-
dependent production of PGI2 (measured as 6-keto-PGF1α 
concentration in effluent) was decreased in the aortic 
rings from the db/db mice as compared to the control 
(148.80 ± 27.20 versus 329.30 ± 68.18 pg/ml, db/db and 
control, resp.; P < 0 05), and COX inhibitors decreased 
PGI2 production in the aorta of the control but not the 
diabetic mice (Figure 5(d)). Furthermore, endothelium in 
the aorta displayed increased VCAM-1 expression compati-
ble with endothelial dysfunction (Figure 6(a)), although there 
were no changes in the eNOS immunostaining intensity 
(Figure 6(c)). In turn, in contrast to the pulmonary 
endothelium, thrombomodulin (CD141) immunostaining 
intensity was decreased (Figure 6(b)). 
4.5. Nonenzymatic Nitration in the Lungs and Aorta. Dot-
blot-assessed general protein nitration was increased in the 
aorta but not in the lungs from the db/db mice, as 
compared with the control; in the lung, only a trend of 
increased nitration was observed (Figure 7(a) and 7(b)). 
Immunohistochemical staining showed only a slight 
increase in the signal of nitrated proteins in the lungs. 
A slight increase in PGIS immunostaining in diabetic lungs 
was also found (Figure 7(c)). 
5. Discussion 
In the present work, we characterized the phenotype of endo-
thelial dysfunction in pulmonary endothelium, as compared 
with peripheral endothelium in the diabetic mice (db/db 
mice). We demonstrated that diabetes induced marked 
ultrastructural changes in pulmonary endothelium that were 
associated with the increased permeability of pulmonary 
microcirculation and impaired NO-dependent function, as 
well as compensatory increase in PGI2 production with 
increased thrombomodulin expression. In contrast, endothe-
lial dysfunction in the aorta was featured by impaired NO-
and PGI2-dependent function and diminished thrombomod-
ulin (CD141) expression. These results suggest a differential 
response of pulmonary vasculature to diabetic insult in terms 
of PGI2-dependent function that might be associated with a 
lesser nonenzymatic protein nitration in the lung, as 
compared with peripheral endothelium and preserved PGI2 
synthase activity. 
Endothelial dysfunction induced by diabetes in periph-
eral circulation in db/db mice has been well documented 
[31–33] and involves (1) increased reactive oxygen species 
production, scavenging of endothelial NO, and increased 
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Figure 5: Endothelial dysfunction in systemic conduit vessel (aorta). (a, b) Impaired endothelium-dependent response to acetylcholine 
(ACh) with preserved endothelium-independent vasodilation in response to sodium nitroprusside (SNP) (control n = 6, diabetes n = 7). 
(c) Preserved basal but impaired ionophore-stimulated production of nitrite in the aortic rings of diabetic mice (control n = 6, 
diabetes n = 7). (d) Impaired basal production of prostacyclin as assessed by concentrations of its stable 6-keto-PGF1α product (control n 
= 6, diabetes n = 6). Data are presented as the means± SEM. ∗P < 0 05. 
nonenzymatic protein nitration [31, 32]; (2) decreased pro-
duction of PGI2 and CD141 expression and impaired 
endothelial-dependent functional responses [31, 34–36]. 
Our results are in linewith the previous studies as regards phe-
notype of endothelial dysfunction in the aorta. Importantly, 
we evaluated the peripheral endothelial phenotype for com-
parison with the analysis of the phenotype of endothelial dys-
function in pulmonary circulation that has been significantly 
less studied, including only few reports in the db/db mice 
[13, 17, 18] and studies in models of diabetes in rats [16, 37]. 
In the present work, we demonstrated that diabetic lungs 
from db/db mice displayed mild inflammatory cell infiltra-
tion and ultrastructural alterations featured by profound 
thickening of the basal membrane, compatible with the pre-
vious reports on diabetic lungs in humans [11, 38, 39]. 
Indeed, thickening of the basal membrane and an impair-
ment of permeability of the alveolar basement membrane 
coexist in diabetes type II in the human lungs, and these 
changes are followed by a decrease in respiratory function 
[6, 40]. Ultrastructural changes of pulmonary endothelium 
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reported here were also featured by activated endothelial cells 
that were, however, less pronounced as high-convoluted 
apical plasmalemma and numerous plasmalemmal vesicles 
reported in transgenic mice model of diabetes type I [41], 
suggesting milder pulmonary endothelial activation in the 
db/db mice. Nevertheless, we found a significant increase 
in endothelial permeability of diabetic pulmonary circula-
tion, as evidenced by increase Kf,c measurements [28] that 
seem also compatible with increased permeability of the 
human lungs from diabetic patients [42]. 
The important finding of this work was the demonstra-
tion of the impairment of NO-dependent function in the 
lungs from the db/db mice. We took advantage of the domi-
nant role of endogenous NO in blunting HPV [43] to study 
functional NO-dependent response in the whole isolated 
lung, instead of choosing isolated pulmonary arteries that 
may reflect NO-dependent function only in the selected part 
of the pulmonary circulation. Our original approach to detect 
impaired NO-dependent function was based on diminished 
modulatory effects of NOS inhibition on HPV response in 
the isolated, perfused lungs [43, 44] supported also by low-
ered cumulative concentrations of NO− 2 in effluents from 
diabetic lungs. On the other hand, eNOS expression in the 
lungs from the control and db/db mice was not different, 
suggesting that alteration of the NO bioavailability was 
responsible for functionally impaired NO-dependent 
response in pulmonary circulation from the db/db mice. 
Endothelium-derived PGI2 is often released in a coupled 
manner with NO [45, 46]. NO deficiency is sometimes linked 
with a decrease in PGI2 production, but in many vascular 
pathologies, PGI2 production may increase in response to 
nitric oxide deficiency [44, 47]. Here, PGI2 production in 
the aorta was reduced, but in the isolated lungs from the 
db/db mice, PGI2 production was augmented. The major 
enzymatic source of PGI2 in the aorta and lung was COX-2, 
as evidenced by the pronounced effect of COX-2 inhibition, 
and this is in line with the notion of COX-2 as the major 
source of systemic PGI2 [48] and important contributor 
to pulmonary endothelial dysfunction [49, 50]. PGI2 
amplifies CD141 expression [21–23]. As shown here, CD141 
immunointensity in the lungs was increased, while it was 
diminished in the aorta, which supports the link between 
PGI2 production and CD141. PGI2 via CD141 activates 
protein C, thus enhancing the anticoagulant mechanism of 
the vascular wall. Reciprocally, activated protein C boosts 
PGI2 production in endothelial cells [51]. 
Thus, pulmonary PGI2 affords potent antiplatelet and 
vasoprotective activity, activating also CD141-dependent 
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anticoagulant mechanisms which might constitute an impor-
tant compensatory mechanism in diabetes offsetting inflam-
matory and thrombotic processes in diabetes involving also 
detrimental COX-2-derived metabolites contributing to 
endothelial dysfunction in diabetes [49, 50, 52] . 
Interestingly, 1-MNA exerts antithrombotic [53] and 
anti-inflammatory [54] properties mediated by the activation 
of COX-2 and PGI2 pathways. It could well be that the 
therapeutic efficacy of 1-MNA reported previously [53–62] 
is linked with the capacity of 1-MNA to stimulate compensa-
tory mechanisms linked to pulmonary PGI2 [44]. Obviously, 
this hypothesis needs to be verified in further studies. 
It is well known that diabetes is associated with increased 
local ROS production in intrapulmonary arteries, as well as in 
systemic circulation [16, 63, 64]. Superoxide anions and NO 
by forming peroxynitrite may lead to nonenzymatic nitration 
of proteins [63, 65] including PGIS; the nitration-mediated 
inactivation of which plays an important role in the develop-
ment of endothelial dysfunction [66–69]. In systemic circula-
tion in diabetes patients, protein nitration affects a number of 
enzymes, including PGIS [64, 70]. Here, we present signifi-
cantly increased general nitration of protein in the aorta, 
and a milder effect (nonstatistically significant) was noticed 
in the lungs. Nonenzymatic nitration may have less signifi-
cance in the diabetic lungs as compared to systemic circula-
tion. Therefore, despite locally increased ROS generation in 
pulmonary vessels [16, 37, 71], in the whole lungs, ROS 
may not play such an important role in pulmonary circula-
tion of the db/db mice as compared to systemic endothelium. 
6. Conclusions 
In conclusion, our results demonstrate that diabetes induced 
profound changes in the lung in the db/db mice involving 
12 Oxidative Medicine and Cellular Longevity 
endothelial ultrastructural changes, increased endothelial 
permeability, and increased vasoreactivity, as well as lung 
inflammation and fibrosis. Impaired NO-dependent pulmo-
nary vascular function was associated with upregulated 
PGI2 and CD141 that might constitute an important com-
pensatory mechanism in pulmonary circulation in diabetes 
that does not operate in endothelium in the aorta, whereby 
endothelial dysfunction is featured by impaired NO, PGI2, 
and CD141. 
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